322 related articles for article (PubMed ID: 27195944)
1. How to determine cardiac ion channels targeted by drugs using the isolated rabbit ventricular wedge model.
Liu G; Liu T; Cohen D; Liu T; Yan GX
J Pharmacol Toxicol Methods; 2016; 81():161-70. PubMed ID: 27195944
[TBL] [Abstract][Full Text] [Related]
2. Assessment of drug-induced proarrhythmia: The importance of study design in the rabbit left ventricular wedge model.
Lu HR; Gallacher DJ; Yan GX
J Pharmacol Toxicol Methods; 2016; 81():151-60. PubMed ID: 27374776
[TBL] [Abstract][Full Text] [Related]
3. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
4. Models of torsades de pointes: effects of FPL64176, DPI201106, dofetilide, and chromanol 293B in isolated rabbit and guinea pig hearts.
Cheng HC; Incardona J
J Pharmacol Toxicol Methods; 2009; 60(2):174-84. PubMed ID: 19524054
[TBL] [Abstract][Full Text] [Related]
5. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
Jacobson I; Carlsson L; Duker G
J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633
[TBL] [Abstract][Full Text] [Related]
6. Electrocardiographic biomarkers to confirm drug's electrophysiological effects used for proarrhythmic risk prediction under CiPA.
Vicente J; Hosseini M; Johannesen L; Strauss DG
J Electrocardiol; 2017; 50(6):808-813. PubMed ID: 28928044
[TBL] [Abstract][Full Text] [Related]
7. New in vitro model for proarrhythmia safety screening: IKs inhibition potentiates the QTc prolonging effect of IKr inhibitors in isolated guinea pig hearts.
Kui P; Orosz S; Takács H; Sarusi A; Csík N; Rárosi F; Csekő C; Varró A; Papp JG; Forster T; Farkas AS; Farkas A
J Pharmacol Toxicol Methods; 2016; 80():26-34. PubMed ID: 27063345
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of an in silico cardiac safety assay: using ion channel screening data to predict QT interval changes in the rabbit ventricular wedge.
Beattie KA; Luscombe C; Williams G; Munoz-Muriedas J; Gavaghan DJ; Cui Y; Mirams GR
J Pharmacol Toxicol Methods; 2013; 68(1):88-96. PubMed ID: 23624022
[TBL] [Abstract][Full Text] [Related]
9. K201, a multi-channel blocker, inhibits clofilium-induced torsades de pointes and attenuates an increase in repolarization.
Hasumi H; Matsuda R; Shimamoto K; Hata Y; Kaneko N
Eur J Pharmacol; 2007 Jan; 555(1):54-60. PubMed ID: 17112502
[TBL] [Abstract][Full Text] [Related]
10. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation.
Eckardt L; Breithardt G; Haverkamp W
J Pharmacol Exp Ther; 2002 Jan; 300(1):64-71. PubMed ID: 11752098
[TBL] [Abstract][Full Text] [Related]
11. Nonselective I(Kr)-blockers do not induce torsades de pointes in the anesthetized rabbit during alpha1-adrenoceptor stimulation.
Lu HR; Remeysen P; De Clerck F
J Cardiovasc Pharmacol; 2000 Dec; 36(6):728-36. PubMed ID: 11117372
[TBL] [Abstract][Full Text] [Related]
12. Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome: effects of beta-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes.
Shimizu W; Antzelevitch C
Circulation; 1998 Nov; 98(21):2314-22. PubMed ID: 9826320
[TBL] [Abstract][Full Text] [Related]
13. Isolated perfused and paced guinea pig heart to test for drug-induced changes of the QT interval.
Cheng HC; Incardona J; McCullough B
J Pharmacol Toxicol Methods; 2006; 54(3):278-87. PubMed ID: 16507347
[TBL] [Abstract][Full Text] [Related]
14. A Proof-of-Concept Evaluation of JTPc and Tp-Tec as Proarrhythmia Biomarkers in Preclinical Species: A Retrospective Analysis by an HESI-Sponsored Consortium.
Boulay E; Abernathy MM; Chui R; Friedrichs GS; Gendron-Parra N; Greiter-Wilke A; Guillon JM; Koerner JE; Menard A; Steidl-Nichols J; Pierson J; Pugsley MK; Rossman EI; Strauss D; Troncy E; Valentin JP; Wisialowski T; Authier S
Int J Toxicol; 2019; 38(1):23-32. PubMed ID: 30567462
[TBL] [Abstract][Full Text] [Related]
15. Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?
Lu HR; Hermans AN; Gallacher DJ
Br J Pharmacol; 2012 Jun; 166(4):1490-502. PubMed ID: 22300168
[TBL] [Abstract][Full Text] [Related]
16. [Ventricular arrhythmias. A potential risk associated with the use of non-cardiovascular drugs prolonging the QT interval].
Calderone V; Cavero I
Minerva Med; 2002 Jun; 93(3):181-97. PubMed ID: 12094149
[TBL] [Abstract][Full Text] [Related]
17. Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block.
Vicente J; Johannesen L; Hosseini M; Mason JW; Sager PT; Pueyo E; Strauss DG
PLoS One; 2016; 11(12):e0163619. PubMed ID: 28036334
[TBL] [Abstract][Full Text] [Related]
18. Synergistic Effect of Dofetilide and Mexiletine on Prevention of Atrial Fibrillation.
Liu G; Xue X; Gao C; Huang J; Qi D; Zhang Y; Dong JZ; Ma CS; Yan GX
J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28522677
[TBL] [Abstract][Full Text] [Related]
19. Modulation of the late sodium current by ATX-II and ranolazine affects the reverse use-dependence and proarrhythmic liability of IKr blockade.
Jia S; Lian J; Guo D; Xue X; Patel C; Yang L; Yuan Z; Ma A; Yan GX
Br J Pharmacol; 2011 Sep; 164(2):308-16. PubMed ID: 21182492
[TBL] [Abstract][Full Text] [Related]
20. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.
Bottino D; Penland RC; stamps A; Traebert M; Dumotier B; Georgiva A; Helmlinger G; Lett GS
Prog Biophys Mol Biol; 2006; 90(1-3):414-43. PubMed ID: 16321428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]